190 related articles for article (PubMed ID: 23174025)
21. Role of IDO in organ transplantation: promises and difficulties.
Löb S; Königsrainer A
Int Rev Immunol; 2009; 28(3-4):185-206. PubMed ID: 19811321
[TBL] [Abstract][Full Text] [Related]
22. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
23. Indoleamine 2,3 dioxygenase and regulation of T cell immunity.
Mellor A
Biochem Biophys Res Commun; 2005 Dec; 338(1):20-4. PubMed ID: 16157293
[TBL] [Abstract][Full Text] [Related]
24. The immunoregulatory role of IDO-producing human dendritic cells revisited.
Terness P; Chuang JJ; Opelz G
Trends Immunol; 2006 Feb; 27(2):68-73. PubMed ID: 16406698
[TBL] [Abstract][Full Text] [Related]
25. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases.
Murakami Y; Hoshi M; Imamura Y; Arioka Y; Yamamoto Y; Saito K
Mediators Inflamm; 2013; 2013():391984. PubMed ID: 23476103
[TBL] [Abstract][Full Text] [Related]
26. Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host.
Zelante T; Fallarino F; Bistoni F; Puccetti P; Romani L
Microbes Infect; 2009 Jan; 11(1):133-41. PubMed ID: 19007906
[TBL] [Abstract][Full Text] [Related]
27. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
28. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
Van den Eynde B
Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
[TBL] [Abstract][Full Text] [Related]
29. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy.
von Bubnoff D; Bieber T
Allergy; 2012 Jun; 67(6):718-25. PubMed ID: 22519427
[TBL] [Abstract][Full Text] [Related]
30. IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive.
Godin-Ethier J; Hanafi LA; Duvignaud JB; Leclerc D; Lapointe R
Mol Immunol; 2011 Oct; 49(1-2):253-9. PubMed ID: 21937116
[TBL] [Abstract][Full Text] [Related]
31. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.
Niinisalo P; Oksala N; Levula M; Pelto-Huikko M; Järvinen O; Salenius JP; Kytömäki L; Soini JT; Kähönen M; Laaksonen R; Hurme M; Lehtimäki T
Ann Med; 2010; 42(1):55-63. PubMed ID: 19941414
[TBL] [Abstract][Full Text] [Related]
32. [Effect of indoleamine 2,3-dioxygenase on transplantation immunity].
Duan X; Cui P; Jiang X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Feb; 22(2):230-3. PubMed ID: 18365624
[TBL] [Abstract][Full Text] [Related]
33. The role of indoleamine 2,3-dioxygenase in transplantation.
Hainz U; Jürgens B; Heitger A
Transpl Int; 2007 Feb; 20(2):118-27. PubMed ID: 17239019
[TBL] [Abstract][Full Text] [Related]
34. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines.
Hwang SL; Chung NP; Chan JK; Lin CL
Cell Res; 2005 Mar; 15(3):167-75. PubMed ID: 15780178
[TBL] [Abstract][Full Text] [Related]
35. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.
Metz R; Duhadaway JB; Kamasani U; Laury-Kleintop L; Muller AJ; Prendergast GC
Cancer Res; 2007 Aug; 67(15):7082-7. PubMed ID: 17671174
[TBL] [Abstract][Full Text] [Related]
36. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression.
Liu H; Liu L; Liu K; Bizargity P; Hancock WW; Visner GA
J Immunol; 2009 Jul; 183(2):1022-31. PubMed ID: 19564344
[TBL] [Abstract][Full Text] [Related]
37. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ino K
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
[TBL] [Abstract][Full Text] [Related]
39. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
40. Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia.
Xu SQ; Wang CY; Zhu XJ; Dong XY; Shi Y; Peng J; Qin P; Sun JZ; Guo C; Ni H; Hou M
Ann Hematol; 2012 Oct; 91(10):1623-31. PubMed ID: 22526360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
